v3.26.1
Segment Reporting - Schedule of Segment Profit or Loss, Including Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Research and development expenses            
Total claseprubart program-related expenses $ 29,504   $ 16,455   $ 47,692 $ 33,045
Total research and development expenses 48,686   26,251   83,214 53,254
General and administrative expenses            
Total general and administrative expenses 13,557   8,869   26,025 16,206
Other income, net 11,267   3,298   16,966 6,964
Net Income (Loss) (50,215) $ (40,834) (31,629) $ (29,511) (91,049) (61,140)
License [Member]            
Revenues [Abstract]            
Revenues 761   193   1,224 1,356
Clinical operation activities [Member]            
Research and development expenses            
Total claseprubart program-related expenses 20,422   12,635   34,578 24,329
CMC activities [Member]            
Research and development expenses            
Total claseprubart program-related expenses 8,998   2,975   12,711 6,779
Preclinical study activity costs [Member]            
Research and development expenses            
Total claseprubart program-related expenses 84   795   403 1,887
Personnel and related costs [Member]            
Research and development expenses            
Total research and development expenses 9,254   5,962   17,888 11,809
General and administrative expenses            
Total general and administrative expenses 4,128   2,794   8,189 5,354
Stock-based compensation expense [Member]            
Research and development expenses            
Total research and development expenses 5,643   2,459   10,491 4,934
General and administrative expenses            
Total general and administrative expenses 6,255   3,247   12,009 6,087
Discovery expenses [Member]            
Research and development expenses            
Total research and development expenses [1] 2,308   168   3,671 1,068
Other costs [Member]            
Research and development expenses            
Total claseprubart program-related expenses 0   50   0 50
Total research and development expenses 1,977   1,207   3,472 2,398
General and administrative expenses            
Total general and administrative expenses $ 3,174   $ 2,828   $ 5,827 $ 4,765
[1] Discovery expenses include costs associated with DNTH212, DNTH312, and other potential product candidates.